← Leaderboards
Henry J Kaminski
Case Western Reserve University
$13,990,719
Attributed
$13,990,719
Total exposure
12
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $3.2M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$23,200,626 · 13
By mechanism
U54$15,965,200 · 7
R24$4,871,314 · 1
R01$1,857,604 · 3
R41$501,508 · 1
R13$5,000 · 1
Top collaborators
No co-investigators on record.
Most similar at Case Western Reserve University
Same institution · by research overlap
- Saptarsi Haldar$3,468,615
- Anthony F. Dimarco$13,052,050
- Sanford D Markowitz$49,710,196
- Richard E Zigmond$14,345,843
- Francisco H Andrade$4,641,776
Others in their field
Top investigators on “Myasthenia Gravis”
- Gary R Cutter · Amc Cancer Research Center$13,341,035
- Diane J Mathis · Joslin Diabetes Center$9,468,337
- Steven J Burden · New York University School Of Medicine$8,858,298
- Kevin C O'Connor · Yale University$5,741,255
- Jon Martin Lindstrom · University Of Pennsylvania$5,517,832
- Lin Mei · University Of Alabama At Birmingham$5,333,682
Research focus
Myasthenia GravisRare DiseasesClinical ResearchInvestigationCholinergic ReceptorsPilot ProjectsNeuromuscular JunctionClinical TrialsPerformanceCollaborationsAdverse EffectsAntibodiesPatient Advocacy GroupProgramsAutoantibodiesIndustryMemberCareerTherapeutic DevelopmentPatient CareScientistFoundationsBiologicalInfrastructure
Grant awards (35)
Rare Disease Network for Myasthenia Gravis$1,454,144
U54 · FY2025 · NS · contact PI
Project 1 Clinical Procedures to Support Research in Myasthenia Gravis (CAPTURE_MG)$467,998
U54 · FY2025 · NS · contact PI
Administrative Core$352,340
U54 · FY2025 · NS · contact PI
Rare Disease Network for Myasthenia Gravis$1,534,359
U54 · FY2023 · NS · contact PI
MGNet Administrative Core$1,032,205
U54 · FY2023 · NS · contact PI
An Open Label Trial of Ixazomib for Treatment Resistant Myasthenia Gravis$157,940
U54 · FY2023 · NS · contact PI
Rare Disease Network for Myasthenia Gravis$1,588,974
U54 · FY2022 · NS · contact PI
MGNet Administrative Core$1,006,465
U54 · FY2022 · NS · contact PI
An Open Label Trial of Ixazomib for Treatment Resistant Myasthenia Gravis$247,178
U54 · FY2022 · NS · contact PI
Rare Disease Network for Myasthenia Gravis$1,490,701
U54 · FY2021 · NS · contact PI
MGNet Administrative Core$949,582
U54 · FY2021 · NS · contact PI
An Open Label Trial of Ixazomib for Treatment Resistant Myasthenia Gravis$222,720
U54 · FY2021 · NS · contact PI
Rare Disease Network for Myasthenia Gravis$1,531,556
U54 · FY2020 · NS · contact PI
MGNet Administrative Core$731,817
U54 · FY2020 · NS · contact PI
An Open Label Trial of Ixazomib for Treatment Resistant Myasthenia Gravis$268,212
U54 · FY2020 · NS · contact PI
Targeted Therapy for Myasthenia Gravis$232,839
R41 · FY2020 · NS · contact PI
Rare Disease Network for Myasthenia Gravis$1,610,173
U54 · FY2019 · NS · contact PI
MGNet Administrative Core$1,050,624
U54 · FY2019 · TR · contact PI
Targeted Therapy for Myasthenia Gravis$268,669
R41 · FY2019 · NS · contact PI
An Open Label Trial of Ixazomib for Treatment Resistant Myasthenia Gravis$268,212
U54 · FY2019 · TR · contact PI
Targeted Therapies for Myasthenia Gravis$1,018,947
R24 · FY2007 · EY · contact PI
Regulation of Extraocular Muscle Development$219,938
R01 · FY2007 · EY · contact PI
Regulation of Extraocular Muscle Development$146,626
R01 · FY2007 · EY · contact PI
Targeted Therapies for Myasthenia Gravis$1,234,479
R24 · FY2006 · EY · contact PI
Regulation of Extraocular Muscle Development$368,629
R01 · FY2006 · EY · contact PI
Targeted Therapies for Myasthenia Gravis$826,182
R24 · FY2005 · EY
Regulation of Extraocular Muscle Development$377,500
R01 · FY2005 · EY
Targeted Therapies for Myasthenia Gravis$872,603
R24 · FY2004 · EY
Targeted Therapies for Myasthenia Gravis$68,238
R24 · FY2004 · EY
Targeted Therapies for Myasthenia Gravis$850,865
R24 · FY2003 · EY
NEUROMUSCULAR TRANSMISSION PROPERTIES OF OCULAR MUSCLE$191,250
R01 · FY2003 · EY
NEUROMUSCULAR TRANSMISSION PROPERTIES OF OCULAR MUSCLE$191,250
R01 · FY2002 · EY
NEUROMUSCULAR TRANSMISSION PROPERTIES OF OCULAR MUSCLE$191,250
R01 · FY2001 · EY
Neurobiology of Eye Movements From Molecules to Behavior$5,000
R13 · FY2001 · NS
NITRIC OXIDE IN NORMAL AND DISEASED OCULAR MUSCLE$171,161
R01 · FY2000 · EY